Visby Medical extends Series E round to include an additional $35 million, totaling more than $135 million raised.
Visby Medical’s CEO reaffirms support for women’s healthcare access, announcing travel expense reimbursement for employees for out-of-state pregnancy-related care.
AACC selects Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology.
Visby Medical today announced Everett Cunningham has been appointed to the company’s Board of Directors.
The Body Agency Collective, Visby Medical, Inc. and CCHCI observe National STD Awareness Month with women’s health initiative on US-Mexico border.
CCHCI among first healthcare providers in the nation to adopt new handheld PCR technology to detect gonorrhea, chlamydia and trichomoniasis in a single visit.
Pediatric urgent care provider among first in the US to adopt new point-of-care STI diagnostic device in adolescents and young adults
Visby Medical today announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority (BARDA)
Investment will accelerate the development of revolutionary rapid, single-use PCR diagnostic technology for home use
Visby Medical™ announced that it will make its debut appearance at the 40th Annual J.P. Morgan Healthcare Conference.
Visby Medical™ today announced Terri S. Bresenham and Scott Edward Mendel have been appointed to the company’s Board of Directors.